Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MBRC-101 |
Synonyms | |
Therapy Description |
MBRC-101 is an antibody-drug conjugate (ADC) comprising an anti-EphA5 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against EPHA5-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 738). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MBRC-101 | MBRC 101|MBRC101 | MBRC-101 is an antibody-drug conjugate (ADC) comprising an anti-EphA5 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against EPHA5-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 738). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |